Ingredion has expanded its pharma and nutraceuticals business by acquiring two pharmaceutical excipients companies based in India. Part of the Company's Nutrition, Health, and Wellness platform, the pharma and nutraceutical business offers functional excipients, anhydrous dextrose and mannitol-based active pharmaceutical ingredients. The acquisition of Amishi Drugs & Chemicals (AD&C) and Mannitab Pharma Specialities will grow the Company's pharmaceutical-grade ingredient portfolio to serve a nearly $1.5 billion global market.

"These investments will allow Ingredion to participate more fully in the growing pharma excipients market as we assemble a critical mass of complementary excipient offerings," said Valdirene Bastos-Evans, senior vice president, president, APAC and global head of pharma, home and beauty.

Due to these strategic investments, the Company's portfolio of functional excipients now includes:

• Binders
• Fillers
• Super-disintegrants
• Lubricants
• Gelatine replacers
• Viscosifiers
• Encapsulation materials
• Parenteral-grade dextrose

Ingredion manufactures these highly functional materials under stringent pharma Good Manufacturing Practices (GMPs) and supports customers globally with regulatory expertise and collaborative technical support. "We are excited to become a leading solutions provider and partner to pharma and nutraceutical formulators globally and add value to our specialties portfolio in this growing market," said Rana Kayal, global director of pharma and nutraceuticals.